Core Insights - BioCryst Pharmaceuticals is focused on developing oral treatments for rare diseases, particularly with its drug ORLADEYO® targeting hereditary angioedema (HAE) [1] - H.C. Wainwright maintains a "Buy" rating for BioCryst, raising its price target from $30 to $32, reflecting confidence in the company's future performance [2] - The FDA's approval of ORLADEYO in an oral pellet formulation is a significant milestone, especially for children, as it addresses a critical need in managing HAE [3] Company Performance - BioCryst's stock is currently priced at $7.60, with a slight increase of 0.33% today, and has fluctuated between $7.57 and $7.92 [4] - The company's market capitalization is approximately $1.6 billion, with a trading volume of 1,923,583 shares today [4] Market Impact - The expanded approval of ORLADEYO is expected to enhance BioCryst's market presence by targeting a younger demographic, positioning the company to capture a larger share of the HAE market [5]

ConversationAdam Lange My name is Adam Lange. I'm the Head of Investor Relations. And on behalf of the entire Zealand Pharma team, we are very pleased to see so many of you today. Thanks a lot for spending the next few hours with us. Today, it is exactly -- almost exactly 2 years ago since we did our last Capital Markets event, our obesity R&D event in December 2023, where for the first time, at least towards a broader audience of investors and analysts, we really articulated the ambition of Zealand Pharma ...

Can anything stop this high-flying drugmaker?Eli Lilly (LLY +3.44%) recently made history. It became the first healthcare stock to reach a market cap of $1 trillion. Although it has since dipped below that, the company's performance over the past few years has been phenomenal, and there could be more of that in store next year. How will 2026 unfold for Eli Lilly? Let's look at two potential developments to watch out for.1. A pair of new launches in weight managementEli Lilly has now firmly established itsel ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

The U.S. Food and Drug Administration has approved Daiichi Sankyo's therapy in combination with Roche's drug for the first-line treatment of patients with a type of breast cancer, the regulator said o... ...

The company has billed this drug as a potential treatment for hypoglycemia caused by hyperinsulinism ("HI"). The news, analyst moves, and severe market reaction have prompted national shareholders rights firm Hagens Berman to open an investigation into whether Rezolute may have previously misled investors about erso's efficacy and commercial prospects. SAN FRANCISCO, Dec. 15, 2025 /PRNewswire/ -- On December 11, 2025, investors in Rezolute, Inc. (NASDAQ: RZLT) saw the price of their shares crater as much as ...

BofA Securities upgraded Bristol Myers Squibb & Co. (NYSE:BMY) , citing near-term catalysts.“What we like about BMY is the valuation coupled with our forecast for a flattish 7-year outlook with risk-adjusted pipeline and favorable mix-related margin tailwinds. When we factor in multiple pipeline-driven upside scenarios (specifically in ’26E), we think the risk-reward is compelling,” analyst Jason Gerberry wrote in an investor note on Monday.BofA upgraded from Neutral to a Buy rating and raised price forecas ...

Core Viewpoint - AB Science has published a new article identifying AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia (AML) and potentially other cancers, highlighting its dual mechanism of action and effectiveness against multidrug resistance [1][2]. Group 1: Drug Candidate Characteristics - AB8939 is characterized as a novel synthetic microtubule destabilizer and ALDH inhibitor, showing potential for treating high-risk AML, particularly in cases with complex karyotypes, MECOM rearrangements, and TP53 mutations [3][4]. - The drug exhibits dual action against proliferating tumor cells through tubulin disruption and quiescent, resistant stem cells via ALDH inhibition, making it a unique therapeutic agent [3][4]. Group 2: Mechanism of Action - AB8939 acts as a microtubule-targeting agent by binding to the colchicine-binding site on β-tubulin, disrupting the microtubule network, leading to cell cycle arrest in the G2/M phase and subsequent apoptosis [4]. - It is a potent inhibitor of ALDH1 and ALDH2 enzymes, which are often overexpressed in tumors and associated with cancer stem cells, tumor progression, and resistance to therapy [4]. Group 3: Efficacy and Resistance - AB8939 demonstrates strong antiproliferative activity against various human cancer cell lines, particularly hematopoietic cancers, with IC₅₀ values in the nanomolar range [4]. - The drug can overcome major mechanisms of drug resistance, including P-glycoprotein (P-gp) efflux and high β3-tubulin expression, retaining efficacy in resistant AML patient blasts [4][5]. Group 4: Clinical Trials - AB8939 is currently being evaluated in a Phase I/II clinical trial (AB18001) for patients with refractory and relapsed AML, with regulatory approval received to initiate the third stage of the study [5][6]. - The first two stages of the trial involved 28 and 13 patients, respectively, determining the maximum tolerated dose (MTD) of 21.3 mg/m² after both three and fourteen consecutive days of treatment [6]. Group 5: Intellectual Property and Regulatory Status - AB8939 is protected by intellectual property rights until 2036 or even 2044, with a patent covering its composition and use in AML treatment granted in multiple countries [7][8][9]. - The drug has received orphan drug designation from both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), granting it marketing exclusivity for 10 years in Europe and 7 years in the US [10].

PRESS RELEASE AB SCIENCE ANNOUNCES A NEW PUBLICATION ON BIORXIV THAT IDENTIFIES AND CHARACTERIZES A NOVEL SMALL SYNTHETIC MOLECULE, AB8939, AS A PROMISING DRUG CANDIDATE FOR TREATING REFRACTORY ACUTE MYELOID LEUKEMIA (AML) AND POTENTIALLY OTHER CANCERS AB8939 is a promising drug candidate for refractory AML, especially for cases with poor prognoses such as complex karyotypes, MECOM rearrangements, and TP53 mutations AB8939 has dual action against both proliferating tumor cells (via tubulin disruption) and q ...

Group 1 - Immuron Limited (NASDAQ:IMRN) is a biotechnology company focused on developing medicines to prevent diarrhea, with a recent setback in its clinical trial for an ETEC hyperimmune bovine colostrum product, which failed to meet its primary endpoint, resulting in a 25.8% drop in share price [2] - The clinical trial was conducted by the Uniformed Services University to assess the product's effectiveness in maintaining gut health during travel and deployment, but Immuron stated that the results do not reflect the performance of its Travelan product due to non-compliance with administration rules and third-party manufacturing [2] - On November 5th, the FDA approved Immuron's IMM-529 drug for a phase 2 clinical trial targeting Clostridioides difficile infection, with the study expected to start in the first half of 2026 and enroll up to 60 participants [3]